Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The study investigate what information individuals with SCD or MCI and their co-participant would like to receive during pre-diagnostic counseling and diagnostic disclosure, and how this information should be conveyed.
Full description
Improved diagnostic work-up and the introduction of disease-modifying treatment have led to a shift towards earlier diagnosis. However, there are a need for better understanding of how best to communicate about biomarker use, assessment, and results in individuals with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
Objective:
The overarching objective of this study is:
To understand what information individuals with SCD or MCI and their co-participant would like to receive during pre-diagnostic counseling and diagnostic disclosure, and how this information should be conveyed.
Methods: a prospective survey study Persons diagnosed with SCD or MCI and co-participants will be recruited consecutively from the memory clinic, Copenhagen University Hospital - Rigshospitalet (Denmark), Toulouse University Hospital, (France), University Medical Centre Ljubljana (Slovenia) and Universitair Ziekenhuis Brussel (Belgium)
Approximately 30 persons and respective co-participants will be included from each hospital over a period of 12 months.
Each participating person and co-participant will be asked to complete a very brief questionnaire immediately after disclosure of the diagnosis, and another questionnaire 2-6 weeks after the disclosure visit.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Inclusion criteria for the co-participant:
120 participants in 2 patient groups
Loading...
Central trial contact
Marie Bruun, MD, PhD; Kristian S Frederiksen, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal